Cedars-Sinai Lymphoma & Myeloma Summit 2026: Science, Innovation, and Care

This conference brings together Southern California lymphoma and myeloma specialists alongside nationally recognized experts to share the latest advances in clinical care and translational research. Clinical update sessions will highlight recently approved therapies, emerging treatment strategies, and promising agents in development. Scientific sessions will feature high-impact basic and translational research, including advances in biomarkers, therapeutic targets, and next-generation cellular therapies, fostering collaboration between laboratory investigators and clinicians to accelerate improvements in patient care.

Satellite session on Oct 16 will provide advanced practitioners, nurses, and coordinators with practical insights into the holistic care of patients undergoing cellular therapy and transplantation.

1. Recognize the role of molecular testing in the diagnosis, classification, and treatment of lymphoma and myeloma.
2. Identify current evidence-based treatment strategies for patients with lymphoma and myeloma.
3. Describe emerging therapies, including bispecific antibodies and CAR T-cell therapies, and their evolving roles in clinical practice.
4. Discuss current and emerging multidisciplinary treatment strategies for lymphoma and myeloma within an interprofessional care framework.

In-Person Fees
In-Person: Healthcare Professional Fee - $0.00 -SOLD OUT
In-Person: Industry Attendee (No Exhibit Booth) - $600.00-SOLD OUT

Virtual Fees
Virtual: Healthcare Professional Fee - $0.00
Virtual: Industry Attendee (No Exhibit Booth) - $550.00

Registration is Now Closed for In-person and we will not be taking any onsite-registrations.  Only Virtual Registration.   

In support of improving patient care, Cedars-Sinai is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement
Cedars-Sinai designates this Live Activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician AMA Attendance
Attendance credit will be provided to other healthcare professionals upon the fulfillment of attendance requirements. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.  

ANCC Credit for Nurses:  This activity is approved for 14.25 ANCC contact hours.

Interprofessional Continuing Education: This activity was planned by and for the healthcare team and learners will receive 11.75 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Mitigation of Relevant Financial Relationships

Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Hitomi Hosoya, MD, PhD
Cedars-Sinai

Course Director, Faculty

Nothing to disclose

Akil Merchant, MD
Cedars-Sinai

Course Director, Faculty

Advisor-Novartis AG|Advisor-Pfizer, Inc.|Advisor-Morphosys|Consultant-Genmab|Consultant-Abbvie|Consultant-Bristol-Myers Squibb|Consultant-Lyell Immunopharma|Consultant-Incyte

Amelie Bilodeau, BSN
Cedar's Sinai

Faculty

Nothing to disclose

Elizabeth Brem, MD
UCI School of Medicine

Faculty

Consultant-BeOne|Speaker-AstraZeneca|Advisor-AstraZeneca|Advisor-Genentech, Inc.|Advisor-Regeneron|Advisor-ADC Therapeutics|Advisor-Posieda (Relationship has ended)|Advisor-Incyte|Advisor-Bristol-Myers Squibb (Relationship has ended)|Speaker-Bristol-Myers Squibb|PrincipalNamedInvestigator-Regeneron|Advisor-Sobi (Relationship has ended)|Advisor-Immunome (Relationship has ended)

Anthony R Colombo, PhD
Cedars-Sinai Academic Pathology

Faculty

Nothing to disclose

Justin Darrah, MD
Cedars-Sinai

Faculty

Advisor-Genmab (Relationship has ended)

Karolina Faysman, NP

Faculty

Speaker-Johnson and Johnson

Sebastian Fernandez-Pol, MD
Stanford University School of Medicine

Faculty

Advisor-Leica Biosystems (Relationship has ended)

Zinaida Good, PhD

Faculty

Advisor-Boom Capital Ventures|Speaker-Sangamo Therapeutics (Relationship has ended)|Independent ContractorResearcher-Sangamo Therapeutics|Speaker-AstraZeneca (Relationship has ended)|PrincipalNamedInvestigator-Kite Pharma, a subsidiary of Gilead Sciences|PrincipalNamedInvestigator-CRISPR Therapeutics

Gillian Gresham, PhD

Faculty

Nothing to disclose

Alex Herrera, MD
City of Hope

Faculty

Consultant-Bristol-Myers Squib Aventis|Consultant-Genentech, Inc.|Consultant-Merck and Company, Inc.|Consultant-AstraZeneca|Consultant-Lilly|Consultant-Genmab|Consultant-Pfizer, Inc.|Consultant-Abbvie|Consultant-Allogene Therapeutics|Consultant-Kite Gilead|Consultant-Incyte|Consultant-ADC Therapeutics|Other: Research -Bristol-Myers Squib Aventis|Other: Research -Genentech, Inc.|Other: Research -Merck and Company, Inc.|Other: Research -Pfizer, Inc.

Maryam Kazerani, PhD
Hematology and Cellular Therapy

Faculty

Nothing to disclose

Kevin Kelly, MD
University of Southern California

Faculty

Speaker-Johnson and Johnson|Speaker-GlaxoSmithKline|Speaker-Pfizer, Inc.|Speaker-AstraZeneca|Speaker-Karyopharm|Speaker-Eli Lilly and Company

Lawrence Liu, MD
Cedars Sinai Medical Center

Faculty

Speaker-MJH Life Sciences (Relationship has ended)|Stock Options or Shareholder-Genentech, Inc.|Stock Options or Shareholder-Pfizer, Inc.

Jens Lohr, MD, PhD

Faculty

Nothing to disclose

Chris T LoPiccolo, MSN
CSMC

Faculty

Nothing to disclose

Joseph C. Lownik, MD
Cedars-Sinai

Faculty

Nothing to disclose

Alyssa Maskell, MSN
Cedars Sinai

Faculty

Nothing to disclose

Christopher Melani, MD
National Institutes of Health

Faculty

Nothing to disclose

Noah Merin, MD, PhD
Cedars-Sinai

Faculty

Consultant-ADC Therapeutics (Relationship has ended)|Consultant-Stemline Therapeutics Inc. (Relationship has ended)|Consultant-Takeda Pharmaceuticals, Inc. (Relationship has ended)|Consultant-Incyte Corporation (Relationship has ended)|Consultant-Servier Pharmaceuticals (Relationship has ended)|Consultant-Ipsen (Relationship has ended)|Consultant-BeiGene USA, Inc. (Relationship has ended)|Advisor-AstraZeneca Pharmaceuticals (Relationship has ended)|Consultant-Janssen Biotech (Relationship has ended)|Advisor-Alexion Pharmaceuticals (Relationship has ended)|Consultant-Karyopharm Therapeutics (Relationship has ended)

Lekha Mikkilineni, MD

Faculty

Advisor-Gilead|Advisor-Jansen, Legend Biotech (Relationship has ended)|Advisor-Caribou (Relationship has ended)|Advisor-Cartesian (Relationship has ended)

Roberto Mina , MD

Faculty

Nothing to disclose

David R. Oveisi, MD
Cedars Sinai Medical Center

Faculty

Consultant-Johnson and Johnson|Speaker-Johnson and Johnson (Relationship has ended)|Advisor-Pfizer, Inc.|Consultant-Bristol-Myers Squibb|PrincipalNamedInvestigator-Johnson and Johnson

Christina Poh, MD

Faculty

Advisor-Acrotech (Relationship has ended)|Advisor-Pfizer, Inc. (Relationship has ended)|Advisor-Incyte (Relationship has ended)|Advisor-Ascentage (Relationship has ended)

Christiane Querfeld, MD
City of Hope

Faculty

Advisor-Kyowa Kirin |Advisor-Helsinn|Advisor-Citius Pharm (Relationship has ended)|PrincipalNamedInvestigator-Kyowa Kirin |Consultant-SLAMBio Therapeutics

Jenn Rocha, RN
UCSF

Faculty

Nothing to disclose

Kamya Sankar, MD
Cedars-Sinai Medical Center

Faculty

Nothing to disclose

Joshua Sasine, MD, PhD
Cedars-Sinai Medical Center

Faculty

Nothing to disclose

Douglas Sborov, MD

Faculty

Consultant-Sanofi-Aventis|Advisor-Johnson and Johnson|Consultant-Pfizer, Inc.|Advisor-Opna Bio|Consultant-Regeneron|Consultant-Bristol-Myers Squibb|Advisor-Legend Biotech|Consultant-GlaxoSmithKline

Swati Sikaria, MD
TMMC

Faculty

Nothing to disclose

Melody Smith, MD

Faculty

Consultant-CVS Caremark|Advisor-A28 Therapeutics

Kevin Tang, MD
Cedars Sinai Medical Center

Faculty

Nothing to disclose

Nicholas Tatonetti, PhD, MS
Cedars-Sinai

Faculty

Advisor-Cari Health (Relationship has ended)|Advisor-WorldQuant Foundry

Niels Weinhold, PhD

Faculty

Advisor-Bristol-Myers Squib Aventis (Relationship has ended)|Advisor-Sanofi-Aventis|Advisor-Johnson and Johnson|Independent ContractorResearcher-Johnson and Johnson|Independent ContractorResearcher-Bristol-Myers Squib Aventis (Relationship has ended)

Emma E Mazzilli, MSN
Cedars-Sinai

Nurse Planner

Nothing to disclose

Valerie Burton, BA
Cedars-Sinai

Planner

Nothing to disclose

Cynthia Medina, PA

Planner

Nothing to disclose